"V sou\u010Dasnosti neexistuje neinvazivn\u00ED vy\u0161et\u0159en\u00ED, kter\u00E9 by p\u0159esn\u011B zhodnotilo v\u00FD\u0161i port\u00E1ln\u00ED hypertenze p\u0159i jatern\u00ED cirh\u00F3ze. Nejsou zn\u00E1my prognostick\u00E9 faktory p\u0159edpov\u00EDdaj\u00EDc\u00ED odpov\u011B\u010F na l\u00E9\u010Dbu betablok\u00E1tory. K hodnocen\u00ED l\u00E9\u010Dby port\u00E1ln\u00ED hypertenze je nutn\u00E9 opakovan\u00E9 invazivn\u00ED vy\u0161et\u0159en\u00ED. Ve skupin\u011B 100 pacient\u016F s jatern\u00ED cirh\u00F3zo bude zhodnocen v\u00FDznam neinvazivn\u00EDch biochemick\u00FDch parametr\u016F jatern\u00ED fibr\u00F3zy a z\u00E1n\u011Btu ve vztahu k v\u00FD\u0161i port\u00E1ln\u00ED hypertenze a k p\u0159edpov\u011Bdi \u00FA\u010Dinnosti l\u00E9\u010Dby betablok\u00E1tory. Bude zhodnocen vliv polymorfism\u016F metaloprotein\u00E1z a beta2 receptor\u016F vzhledem na rozvoj komplikac\u00ED port\u00E1ln\u00ED hypertenze a \u00FA\u010Dinnosti l\u00E9\u010Dby betablok\u00E1tory. Bude posoutzen vztah neinvazivn\u00EDch kardiologick\u00FDch parametr\u016F na rozvoj komplikac\u00ED port\u00E1ln\u00ED hypertenze." . "5"^^ . . . . "1"^^ . "Non-invasive parameters in the evaluation of portal hypertension in patients with liver cirrhosis and their significance for the evolution of cardial complications."@en . " portal hypertension" . . "NT12290" . " noninvasive markers of fibrosi" . "2014-03-21+01:00"^^ . . "There is no noninvasive method, which could evaluate the degree of portal hypertension precisely. No factors predicting the response to the treatment with betablockers are known and for the evaluation of response, repeated HVPG measurement is necessary. In the group of 100 patients with liver cirrhosis the role of noninvasive parameters of hepatic fibrosis and inflammation in the evaluation of portal hypertension and treatment response to betablockers will be assessed. The role of metalloproteinases and beta2 adrenergic receptors gene polymorphisms for the evolution of portal hypertension complications and for the betablockers efficacy will be evaluated. The role of noninvasice cardiologic parameters for the progression of portal hypertension complications will be evaluated."@en . "2011-06-01+02:00"^^ . "2015-01-22+01:00"^^ . . "0"^^ . "Neinvazivn\u00ED parametry v hodnocen\u00ED port\u00E1ln\u00ED hypertenze p\u0159i jatern\u00ED cirh\u00F3ze a jejich v\u00FDznam pro vznik kardi\u00E1ln\u00EDch komplikac\u00ED." . "Cirrhosis" . . "0"^^ . . "http://www.isvav.cz/projectDetail.do?rowId=NT12290"^^ . . . . "Cirrhosis; portal hypertension; noninvasive markers of fibrosi; metalloproteinases polymorphis; beta2-adrenergic receptor poly"@en . . . " metalloproteinases polymorphis" . . . . . "5"^^ . "2015-06-30+02:00"^^ .